Anna Jamnitski

The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept

Anna Jamnitski, G. M. Bartelds, Michael T. Nurmohamed et al. · Annals of the Rheumatic Diseases · 2010 · 178 citations

Life Sciences, Immunology, Pharmacotherapy +17

Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients

Anna Jamnitski, C. Krieckaert, Michael T. Nurmohamed et al. · Annals of the Rheumatic Diseases · 2011 · 143 citations

Medicine, Pharmacology, Pharmacotherapy +13

Comparison of long‐term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity

C. Krieckaert, Anna Jamnitski, Michael T. Nurmohamed et al. · Arthritis & Rheumatism · 2012 · 69 citations

Life Sciences, Internal Medicine, Pharmacotherapy +17

Beneficial effect of 1-year etanercept treatment on the lipid profile in responding patients with rheumatoid arthritis: the ETRA study

Anna Jamnitski, I.M. Visman, Matthew Peters et al. · Annals of the Rheumatic Diseases · 2010 · 47 citations

Medicine, Clinical Sciences, Pharmacology +12

MUC5B promoter variant rs35705950 and rheumatoid arthritis associated interstitial lung disease survival and progression

Pierre‐Antoine Juge, Joshua J. Solomon, Coline H.M. van Moorsel et al. · Seminars in Arthritis and Rheumatism · 2021 · 46 citations · Full text

Life Sciences, Genetics, Molecular Genetics +13